Spinal cord bioavailability of methylprednisolone after intravenous and intrathecal administration: The role of P-glycoprotein

Anesthesiology

Volumn 92, Issue 1, 2000, Pages 156-163

  Koszdin, Kari L ^a   Shen, Danny D ^a   Bernards, Christopher M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Friend leukemia virus strain B; mdr 1a 1b ( ); Mice

Indexed keywords

GLYCOPROTEIN P; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DISTRIBUTION; FEMALE; LUMBAR SPINAL CORD; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SWINE; THORACIC SPINAL CORD; TISSUE DISTRIBUTION;

EID: 0033961357     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-200001000-00027     Document Type: Article

References (21)

1. Bracken MB, Shepard MJ, Holford TR, Leo-Summers L, Aldrich EF, Fazl M, Fehlings M, Herr DL, Hitchon PW, Marshall LF, Nockels RP, Pascale V, Perot PL, Jr, Piepmeier J, Sonntag VK, Wagner F, Wilberger JE, Winn HR, Young W: Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury: Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 1997; 277:1597-604
2. Bracken MB, Shepard MJ, Collins WF, Jr, Holford TR, Baskin DS, Eisenberg HM, Flamm E, Leo-Summers L, Maroon JC, Marshall LF, Phanor LP, Piepmeier J, Sonntag VKH, Wagner FC, Wilberger JL, Winn HR, Young W: Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data: Results of the second National Acute Spinal Cord Injury Study [see comments]. J Neurosurg 1992; 76:23-31
3. Galandiuk S, Raque G, Appel S, Polk HC Jr: The two-edged sword of large-dose steroids for spinal cord trauma. Ann Surg 1993; 218: 419-27
4. Gerndt SJ, Rodriguez JL, Pawlik JW, Taheri PA, Wahl WL, Micheals AJ, Papadopoulos SM: Consequences of high-dose steroid therapy for acute spinal cord injury. J Trauma 1997; 42:279-84
5. Drummond JC, Moore SS: The influence of dextrose administration on neurologic outcome after temporary spinal cord ischemia in the rabbit. ANESTHESIOLOGY 1989; 70:64-70
6. Derendorf H, Mollmann H, Krieg M, Tunn S, Mollmann C, Barth J, Rothig HJ: Pharmacodynamics of methylprednisolone phosphate after single intravenous administration to healthy volunteers. Pharm Res 1991; 8:263-8
7. George ER, Scholten DJ, Buechler CM, Jordan-Tibbs J, Mattice C, Albrecht RM: Failure of methylprednisolone to improve the outcome of spinal cord injuries. Am Surg 1995; 61:659-664
8. Gerhart KA, Johnson RL, Menconi J, Hoffman RE, Lammertse DP: Utilization and effectiveness of methylprednisolone in a population-based sample of spinal cord injured persons. Paraplegia 1995; 33: 316-21
9. Saitoh H, Hatakeyama M, Eguchi O, Oda M, Takada M: Involvement of intestinal P-glycoprotein in the restricted absorption of methylprednisolone from rat small intestine. J Pharm Sci 1998; 87:73-5
10. Sugawara I, Hamada H, Tsuruo T, Mon S: Specialized localization of P-glycoprotein recognized by MRK 16 monoclonal antibody in endothelial cells of the brain and the spinal cord. Jpn J Cancer Res 1990; 81:727-30
11. Prasad VK, Ho B, Haneke C: Simultaneous determination of prednisolone acetate, prednisolone, prednisone, cortisone and hydrocortisone in swine plasma using solid-phase and liquid-liquid extraction techniques. J Chromatogr 1986; 378:305-16
12. Braughler JM, Hall ED: Pharmacokinetics of methylprednisolone in cat plasma and spinal cord following a single intravenous dose of the sodium succinate ester. Drug Metab Dispos 1982; 10:551-2
13. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komano T, Hori R: Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 1992; 267(34):24248-52
14. van Kalken CK, Broxterman HJ, Pinedo HM, Feller N, Dekker H, Lankelma J, Giaccone G: Cortisol is transported by the multidrug resistance gene product P-glycoprotein. Br J Cancer 1993; 67:284-9
15. van Asperen J, Mayer U, van Tellingen O, Beijnen JH: The functional role of P-glycoprotein in the blood-brain barrier. J Pharm Sci 1997; 86:881-4
16. Schinkel AH, Wagenaar E, Mol CA, van Deemter L: P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996; 97: 2517-24
17. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P: Absence of the mdrla P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995; 96:1698-705
18. Meijer OC, de Lange EC, Breimer DD, de Boer AG, Workel JO, de Kloet ER: Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdrlA P-glycoprotein knockout mice. Endocrinology 1998; 139:1789-93
19. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, van der Valk MA, Voordouw AC, Spits H, van Tellingen O, Zijlmans JM, Fibbe WE, Borst P: Normal viability and altered pharmacokinetics in mice lacking mdrl-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci U S A 1997; 94:4028-33
20. +-ATPase activity: Dose-response analysis during 1st hour after contusion injury in the cat. J Neurosurg 1982, 57:247-53.
21. Hall ED, Wolf DL, Braughler JM: Effects of a single large dose of methylprednisolone sodium succinate on experimental posttraumatic spinal cord ischemia: Dose-response and time-action analysis. J Neurosurg 1984; 61:124-30